Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e.g., fat, bone, and cartilage) presumed to arise from aberrant development or differentiation of mesenchymal stem cells (MSCs). Appropriate control of stem cell maintenance versus differentiation allows for normal connective tissue development. Current theories suggest that loss of this control-through accumulation of genetic lesions in MSCs at various points in the differentiation process -leads to development of sarcomas, including undifferentiated, high grade sarcoma tumors . The initiation of stem cell differentiation is highly associated with alteration of gene expression, which depends on chromatin remodeling [2, 3]. Epigenetic chromatin modifying agents have been shown to induce cancer cell differentiation and are currently being used clinically to treat cancer. This review will focus on the importance of epigenetic chromatin remodeling in the context of mesenchymal stem cells, sarcoma tumorigenesis and differentiation therapy.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: March 1, 2010
More about this publication?
- Current Stem Cell Research & Therapy publishes frontier reviews on all aspects of basic research on stem cells and their uses in clinical therapy. The journal's aim is to publish the highest quality review articles in the field. The journal is essential reading for all researchers and clinicians involved in stem cells.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites